ClinicalTrials.gg

Program

HSK31679

A development code. Also written as “HSK31679 80mg”, “HSK31679 160mg” and “[14C]HSK31679”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Hypercholesterolemia, led by Haisco Pharmaceutical Group.

Furthest: phase 3, since May 6, 20265 company-led studies, 2 open or runningNext primary completion: Jun 30, 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Haisco Pharmaceutical Group52 open or runningphase 3since May 6, 2026Aug 24, 2022Jun 30, 2029phase 3 · NCT07581951

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 24, 2022First study: phase 1 study in HealthyFirst studyNCT05531097 · 96 enrolled · China
  2. Mar 9, 2023Phase 2 study in HypercholesterolemiaNCT05795517 · 210 enrolled · China
  3. Dec 5, 2023Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT06168383 · 186 enrolled · China
  4. Feb 6, 2024Phase 1 study in HealthyNCT06258746 · 6 enrolled · China
  5. May 6, 2026Phase 3 study in Non-alcoholic Fatty Liver DiseasePhase 3 reachedNCT07581951 · 886 planned · China

Ahead

  1. Jun 30, 2029Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseNCT07581951

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07581951Non-alcoholic Fatty Liver Disease · China3RecruitingJun 30, 2029886
NCT06258746Healthy · China1Active, not recruitingDec 21, 20236
NCT06168383Non-alcoholic Fatty Liver Disease · China2CompletedDec 12, 2025186
NCT05795517Hypercholesterolemia · China2CompletedFeb 20, 2024210
NCT05531097Healthy · China1CompletedSep 21, 202296

How it is read

Names in the registry

  • “HSK31679”, 2 entries
  • “HSK31679 80mg”, 1 entry
  • “HSK31679 160mg”, 1 entry
  • “[14C]HSK31679”, 1 entry
  • “HSK31679 low dose”, 1 entry

Codes read as this program: HSK31679.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.